Skip Nav Destination
Issues
1 November 2009
-
Cover Image
Cover Image
A recombinant adenovirus genetically designed to replicate in colorectal carcinoma cells was engineered to express the Na/I symporter in target cells only. In vivo, SPECT imaging was used to monitor the propagation of the virus in tumors and to establish the ideal timing for metabolic radiotherapy. For further details, please see the article by Peerlinck and co-workers on page 6595 in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
CCR Translations
Molecular Pathways
Perspective
Reviews
Human Cancer Biology
Circulating Mesothelin Protein and Cellular Antimesothelin Immunity in Patients with Pancreatic Cancer
Fabian Mc. Johnston; Marcus C.B. Tan; Benjamin R. Tan, Jr.; Matthew R. Porembka; Elizabeth M. Brunt; David C. Linehan; Peter O. Simon, Jr.; Stacey Plambeck-Suess; Timothy J. Eberlein; Karl Erik Hellstrom; Ingegerd Hellstrom; William G. Hawkins; Peter Goedegebuure
Genomic and Expression Profiling of Glioblastoma Stem Cell–Like Spheroid Cultures Identifies Novel Tumor-Relevant Genes Associated with Survival
Aurélie Ernst; Stefanie Hofmann; Rezvan Ahmadi; Natalia Becker; Andrey Korshunov; Felix Engel; Christian Hartmann; Jörg Felsberg; Michael Sabel; Heike Peterziel; Moritz Durchdewald; Jochen Hess; Sebastian Barbus; Benito Campos; Anna Starzinski-Powitz; Andreas Unterberg; Guido Reifenberger; Peter Lichter; Christel Herold-Mende; Bernhard Radlwimmer
Cancer Therapy: Preclinical
Systemic Inhibition of Transforming Growth Factor-β in Glioma-Bearing Mice Improves the Therapeutic Efficacy of Glioma-Associated Antigen Peptide Vaccines
Ryo Ueda; Mitsugu Fujita; Xinmei Zhu; Kotaro Sasaki; Edward R. Kastenhuber; Gary Kohanbash; Heather A. McDonald; Jay Harper; Scott Lonning; Hideho Okada
Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc Functions
Mario I. Vega; Sara Huerta-Yepez; Melisa Martinez-Paniagua; Bernardo Martinez-Miguel; Rogelio Hernandez-Pando; Cesar R. González-Bonilla; Paul Chinn; Nabil Hanna; Kandasamy Hariharan; Ali R. Jazirehi; Benjamin Bonavida
Targeted Radionuclide Therapy Using a Wnt-Targeted Replicating Adenovirus Encoding the Na/I Symporter
Inge Peerlinck; Andrew Merron; Patrick Baril; Sophie Conchon; Pilar Martin-Duque; Cécilia Hindorf; Jerome Burnet; Miguel Quintanilla; Mohan Hingorani; Richard Iggo; Nick R. Lemoine; Kevin Harrington; Georges Vassaux
Interferon-γ–Dependent Infiltration of Human T Cells into Neuroblastoma Tumors In vivo
Gregor S.D. Reid; Xiaochuan Shan; Christina M. Coughlin; Wiem Lassoued; Bruce R. Pawel; Leonard H. Wexler; Carol J. Thiele; Maria Tsokos; Jack L. Pinkus; Geraldine S. Pinkus; Stephan A. Grupp; Robert H. Vonderheide
The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) Enhances the Radiation Responsiveness of Lung and Colorectal Tumor Xenografts
Aoife M. Shannon; Brian A. Telfer; Paul D. Smith; Muhammed Babur; Armelle Logie; Robert W. Wilkinson; Camille Debray; Ian J. Stratford; Kaye J. Williams; Stephen R. Wedge
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer
Dongwei Zhang; Tiffany A. LaFortune; Savitri Krishnamurthy; Francisco J. Esteva; Massimo Cristofanilli; Ping Liu; Anthony Lucci; Balraj Singh; Mien-Chie Hung; Gabriel N. Hortobagyi; Naoto T. Ueno
Imaging, Diagnosis, Prognosis
Altered Tissue 3′-Deoxy-3′-[18F]Fluorothymidine Pharmacokinetics in Human Breast Cancer following Capecitabine Treatment Detected by Positron Emission Tomography
Laura M. Kenny; Kaiyumars B. Contractor; Justin Stebbing; Adil Al-Nahhas; Carlo Palmieri; Sami Shousha; R. Charles Coombes; Eric O. Aboagye
Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging
James P.B. O'Connor; Richard A.D. Carano; Andrew R. Clamp; Jed Ross; Calvin C.K. Ho; Alan Jackson; Geoff J.M. Parker; Chris J. Rose; Franklin V. Peale; Michel Friesenhahn; Claire L. Mitchell; Yvonne Watson; Caleb Roberts; Lynn Hope; Sue Cheung; Hani Bou Reslan; Mary Ann T. Go; Glenn J. Pacheco; Xiumin Wu; Tim C. Cao; Sarajane Ross; Giovanni A. Buonaccorsi; Karen Davies; Jurjees Hasan; Paula Thornton; Olivia del Puerto; Napoleone Ferrara; Nicholas van Bruggen; Gordon C. Jayson
Cancer Therapy: Clinical
A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors
Roger B. Cohen; Suzanne F. Jones; Charu Aggarwal; Margaret von Mehren; Jonathan Cheng; David R. Spigel; F. Anthony Greco; Mariangela Mariani; Maurizio Rocchetti; Roberta Ceruti; Silvia Comis; Bernard Laffranchi; Jurgen Moll; Howard A. Burris
A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies
Howard A. Burris, III; Charles W. Taylor; Suzanne F. Jones; Kevin M. Koch; Melissa J. Versola; Niki Arya; Ronald A. Fleming; Deborah A. Smith; Lini Pandite; Neil Spector; George Wilding
Phase I Biodistribution and Pharmacokinetic Study of Lewis Y–Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers
Rebecca A. Herbertson; Niall C. Tebbutt; Fook-Thean Lee; David J. MacFarlane; Bridget Chappell; Noel Micallef; Sze-Ting Lee; Timothy Saunder; Wendie Hopkins; Fiona E. Smyth; David K. Wyld; John Bellen; Daryl S. Sonnichsen; Martin W. Brechbiel; Carmel Murone; Andrew M. Scott
A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia
Alexander E. Perl; Margaret T. Kasner; Donald E. Tsai; Dan T. Vogl; Alison W. Loren; Stephen J. Schuster; David L. Porter; Edward A. Stadtmauer; Steven C. Goldstein; Noelle V. Frey; Sunita D. Nasta; Elizabeth O. Hexner; Jamil K. Dierov; Cezary R. Swider; Adam Bagg; Alan M. Gewirtz; Martin Carroll; Selina M. Luger
Letters to the Editor
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds